Dr. Michael C. Montalto
PhD, Executive Director and Head of
Translational Pathology and Biomarker Sciences in
Translational Medicine at Bristol-Myer Squibb
Dr. Montalto is a research and development leader with a broad range of experience at the executive level including R&D, clinical, regulatory, medical and scientific affairs. He is currently the Executive Director and Head of Translational Pathology and Biomarker Sciences in Translational Medicine at Bristol-Myer Squibb. In this role he leads genomics, genetics, flow cytometry, histo-chemistry and pathology laboratories in support of global clinical trials, exploratory biomarker research and companion diagnostics. Prior to this role, Dr. Montalto was a co-founder and executive of Omnyx, LLC, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center that commercialized diagnostic pathology imaging and software products through GE Healthcare. He has patented and published on novel digital pathology-based multiplexing technology (MultiOmyx™, Clarient/Neogenomics) for oncology biomarker discovery. He has designed and led global clinical trials for digital pathology devices and served as chair of the regulatory taskforce of the Digital Pathology Association (DPA). He currently serves as an executive member of the Board of Directors of the DPA as President-elect and Treasurer. He has served as a member of NIH study sections for in vivo molecular imaging centers. Dr. Montalto earned his PhD in tumor biology from Albany Medical College and received his post-doctoral training in anti-inflammatory drug discovery and whole animal physiology at Brigham and Women’s Hospital, Harvard Medical School.